Aquestive Therapeutics, Inc. (AQST)Healthcare | Drug Manufacturers - Specialty & Generic | Warren, United States | NasdaqGM
4.06 USD
-0.06
(-1.456%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:49 a.m. EDT
The long-term investment case is severely compromised by deteriorating fundamentals. Despite a recent recovery in share price, the company is burning cash with negative operating and free cash flows, and the balance sheet shows negative book value. The market has correctly priced this as a distressed asset, reflected in the negative forward P/E and the massive gap between the current price and the $8.88 analyst mean target, which relies on a turnaround that hasn't materialized yet. The short-term outlook remains cautious; while the stock has rallied off its lows, the heavy put writing indicates that traders are still bracing for volatility or further drops. With no dividend to provide income and a history of significant value destruction over the last seven years, this is a speculative hold at best, not a core investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.042062 |
| AutoETS | 0.043503 |
| AutoARIMA | 0.043539 |
| MSTL | 0.044712 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 4.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.442 |
| Market Cap | 509,395,968 |
| Forward P/E | -9.02 |
| Beta | 1.45 |
| Profit Margins | -137.08% |
| Website | https://www.aquestive.com |
As of July 11, 2026, 5:49 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (especially the $2 strike) compared to negligible call volume. While there is some interest in upside strikes ($6-$8), the overwhelming capital allocation is defensive, suggesting a fear of further decline rather than a bet on a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.00995028 |
| Address1 | 30 Technology Drive |
| All Time High | 20.696 |
| All Time Low | 0.618 |
| Ask | 5.12 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,741,180 |
| Average Daily Volume3 Month | 1,808,632 |
| Average Volume | 1,808,632 |
| Average Volume10Days | 1,741,180 |
| Beta | 1.445 |
| Bid | 2.92 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | -0.274 |
| City | Warren |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.06 |
| Current Ratio | 4.1 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.12 |
| Day Low | 3.9912 |
| Display Name | Aquestive Therapeutics |
| Earnings Call Timestamp End | 1,778,760,000 |
| Earnings Call Timestamp Start | 1,778,760,000 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -55,342,000 |
| Ebitda Margins | -1.10087 |
| Enterprise To Ebitda | -7.99 |
| Enterprise To Revenue | 8.796 |
| Enterprise Value | 442,174,496 |
| Eps Current Year | -0.42 |
| Eps Forward | -0.45 |
| Eps Trailing Twelve Months | -0.61 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.2286 |
| Fifty Day Average Change | -0.16860008 |
| Fifty Day Average Change Percent | -0.039871372 |
| Fifty Two Week Change Percent | 0.995028 |
| Fifty Two Week High | 7.55 |
| Fifty Two Week High Change | -3.4900002 |
| Fifty Two Week High Change Percent | -0.46225166 |
| Fifty Two Week Low | 2.93 |
| Fifty Two Week Low Change | 1.1299999 |
| Fifty Two Week Low Change Percent | 0.38566548 |
| Fifty Two Week Range | 2.93 - 7.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,532,525,400,000 |
| Float Shares | 114,568,576 |
| Forward Eps | -0.45 |
| Forward P E | -9.0222225 |
| Free Cashflow | -25,688,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 147 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.63453996 |
| Gross Profits | 31,899,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03095 |
| Held Percent Institutions | 0.58827996 |
| Implied Shares Outstanding | 125,466,988 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. |
| Long Name | Aquestive Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 509,395,968 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_8142504 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -68,911,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 509,395,971 |
| Number Of Analyst Opinions | 9 |
| Open | 4.09 |
| Operating Cashflow | -43,838,000 |
| Operating Margins | -0.29101 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 908 941 1900 |
| Pre Market Change | 0.05000019 |
| Pre Market Change Percent | 1.2315319 |
| Pre Market Price | 4.11 |
| Pre Market Time | 1,784,028,711 |
| Previous Close | 4.12 |
| Price Eps Current Year | -9.666667 |
| Price Hint | 4 |
| Price To Book | -14.817518 |
| Price To Sales Trailing12 Months | 10.132998 |
| Profit Margins | -1.37079 |
| Quick Ratio | 3.704 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -1.45631 |
| Regular Market Day High | 4.12 |
| Regular Market Day Low | 3.9912 |
| Regular Market Day Range | 3.9912 - 4.12 |
| Regular Market Open | 4.09 |
| Regular Market Previous Close | 4.12 |
| Regular Market Price | 4.06 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,612,698 |
| Return On Assets | -0.28708 |
| Revenue Growth | 0.657 |
| Revenue Per Share | 0.442 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 125,466,988 |
| Shares Percent Shares Out | 0.1275 |
| Shares Short | 15,996,883 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 15,239,186 |
| Short Name | Aquestive Therapeutics, Inc. |
| Short Percent Of Float | 0.13350001 |
| Short Ratio | 7.02 |
| Source Interval | 15 |
| State | NJ |
| Symbol | AQST |
| Target High Price | 11.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.88889 |
| Target Median Price | 9.0 |
| Total Cash | 110,734,000 |
| Total Cash Per Share | 0.883 |
| Total Debt | 43,581,000 |
| Total Revenue | 50,271,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.61 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.844525 |
| Two Hundred Day Average Change | -0.7845249 |
| Two Hundred Day Average Change Percent | -0.16194053 |
| Type Disp | Equity |
| Volume | 1,612,698 |
| Website | https://www.aquestive.com |
| Zip | 7,059 |